Plasmodium vivax and Plasmodium ovale form dormant liver hypnozoites that can reactivate
weeks to months following initial infection. Malaria recurrences caused by relapses are an …

Background In most of the Americas, the recommended treatment to prevent relapse of
Plasmodium vivax malaria is primaquine at a total dose of 3.5 mg per kilogram of body …

Background With over a hundred million annual infections and rising morbidity and mortality,
Plasmodium vivax malaria remains largely a neglected disease. In particular, the …

Background Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal
dosing regimen remains unclear. We undertook a systematic review and individual patient …

Background Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria
despite increasing reports of treatment failure. We did a systematic review and meta …

Introduction: Relapses are important contributors to illness and morbidity in Plasmodium
vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required …

Background Primaquine is the only licensed drug for eradicating Plasmodium vivax
hypnozoites and, therefore, preventing relapses of vivax malaria. It is a vital component of …

Background Primaquine has been the only widely available hypnozoitocidal anti-malarial
drug for half a century. Despite this its clinical efficacy is poorly characterized resulting in a …

Background Plasmodium vivax has the widest geographic distribution of the human malaria
parasites and nearly 2.5 billion people live at risk of infection. The control of P. vivax in …

Background Primaquine radical cure is used to treat dormant liver-stage parasites and
prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We …